CSL Vifor

Ferinject® (ferric carboxymaltose)

Dosing and administration guide

Ferinject® is indicated for the treatment of iron deficiency when:
- **oral iron preparations are ineffective.**
- **oral iron preparations cannot be used.**
- **there is a clinical need to deliver iron rapidly.**

The diagnosis of iron deficiency must be based on laboratory tests.[1]

Safety information:

The most serious adverse drug reaction with Ferinject® (ferric carboxymaltose) is anaphylactic reactions with a frequency of rare (≥1/10,000 to <1/1,000). Ferinject® should only be administered when staff trained to evaluate and manage anaphylactic reactions is immediately available, in an environment where full resuscitation facilities can be assured. The patient should be observed for adverse effects for at least 30 minutes following each Ferinject® administration.[1]

Please refer to the Ferinject® SmPC for complete tolerability information.

Click Here for Prescribing Information and Adverse Event Reporting

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA YellowCard in Google Play or Apple App Store. Adverse events should also be reported to Vifor Pharma UK Limited (Tel: 01276853633) Email: medicalinfo_UK@viforpharma.com

UK-FCM-2500051
Date of preparation: March 2025

ferinject®
ferric carboxymaltose

Ferinject® (ferric carboxymaltose)

Summary of Dosing and Administration instructions for Adults and Adolescents aged 14 years and above[1]

The maximum weekly dose is 1000 mg iron, equivalent to 20 mL Ferinject®. If the total iron need is higher, then the administration of an additional dose should be a minimum of 7 days apart from the first dose.

For dosing considerations in patients aged 1-13 years please refer to the SmPC. Ferinject® is not recommended for use in children below 1 year of age.

IV infusion:
a single dose must not exceed 1000 mg iron or 20 mg/kg body weight.

IV injection:
a single dose must not exceed 1000 mg iron or 15 mg/kg body weight

For the maximum weekly dose for patients with body weight <35 kg, please refer to the SmPC.

A single maximum daily dose of 200 mg iron should not be exceeded in haemodialysis-dependent chronic kidney disease patients aged 14 years and above.

The individual total iron need for repletion using Ferinject® is determined based on the patient's body weight and haemoglobin (Hb) level. Two doses may be required to replenish the total iron need.

Determination of the total iron need.

Hb	Patient body weight	
g/dL	35 kg to <70 kg	70 kg and above
<10	1,500 mg	2,000 mg
10 to <14	1,000 mg	1,500 mg
≥14	500 mg	500 mg

Ferinject® administration by IV infusion or injection based on dose

IV Infusion[1]

Dose	Dilution range*	Minimum administration time
100 to 200 mg	1 – 50 mL	No time limit
>200 to 500 mg	1 – 100 mL	6 minutes
>500 to 1000 mg	1 – 250 mL	15 minutes

For stability reasons, dilution to concentrations less than 2 mg iron/mL are not permissible.

*** Maximum amount of sterile 0.9% m/V sodium chloride solution.**

IV Injection[1]

Dose	Administration time/rate
100 to 200 mg	No time limit
>200 to 500 mg	100 mg/min
>500 to 1000 mg	15 minutes

Administer undiluted Ferinject® by the intravenous injection route.

No test dose requirement.[2]

UK-FCM-2500051
Date of preparation: March 2025

ferinject®
ferric carboxymaltose

Ferinject UK Prescribing Information

CSL Vifor

Ferric Carboxymaltose 50mg iron/mL dispersion for injection/infusion

10ml/5 vials, 20ml/1 vial

Click here or scan the QR code to access UK prescribing information for Ferinject® (ferric carboxymaltose)

Stay up to date

CLICK HERE TO REGISTER FOR

Resources to support your clinical practice

Promotional content delivered by national experts

New events

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA YellowCard in Google Play or Apple App Store. Adverse events should also be reported to Vifor Pharma UK Limited (Tel: 01276853633) Email: medicalinfo_UK@viforpharma.com

1. Ferinject® Summary of Product Characteristics. 2. EMA. Intravenous iron-containing medicinal products – referral. Available at: https://www.ema.europa.eu/en/medicines/human/referrals/intravenous-iron-containing-medicinal-products (Accessed March 2025).

UK-FCM-2500051
Date of preparation: March 2025

ferinject®
ferric carboxymaltose